Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Stalevo Stories

2014-04-10 08:28:50

DUODOPA improves quality of life for those with advanced stages of disease MONTREAL, April 10, 2014 /CNW/ - AbbVie today announced that a new treatment called DUODOPA(® )(levodopa/carbidopa intestinal gel) is now available to Canadians with advanced Parkinson's disease. Currently, more than 100,000 Canadians live with Parkinson's - a progressive, incurable neurological disorder that can significantly affect the quality of life of patients, their families and caregivers. DUODOPA is approved...

2014-04-03 12:30:25

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management SummaryGBI Research has released the pharma report "Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management". The...

2014-03-04 16:24:31

Upon completing the survey, Find a Cure Panel will make a donation to a non-profit of your choice LOS ANGELES, March 4, 2014 /PRNewswire/ -- Find a Cure Panel specializes in patient research for serious and rare diseases and conditions, including Parkinson's. They currently have a confidential and anonymous online survey for PD. Both patients and caregivers can qualify. Please read the below and consider participating if you qualify. Survey for patients and caregivers who are on Levodopa...

2013-10-02 12:29:35

Results from the Phase 2/3 EASED Trial Demonstrate an Increase of Approximately Three Hours in ON Time Without Troublesome Dyskinesia for Patients Taking ADS-5102 Compared to Placebo MONTREAL and EMERYVILLE, Calif., Oct. 2, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED((TM)) clinical trial of ADS-5102 at the World Parkinson's Congress. ADS-5102 is Adamas' proprietary long-acting capsule formulation of amantadine HCl in development...

2013-07-30 12:28:17

Once-Daily Dopamine Agonists Will Progressively Dominate This Market-Leading Drug Class, According to a New Report from Decision Resources BURLINGTON, Mass., July 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of key current brands and the launch of three new therapies will help sustain the Parkinson's disease (PD) market throughout the 2012-2022 forecast period,...

2013-06-19 08:29:22

NESS ZIONA, Israel, June 19, 2013 /PRNewswire/ -- NeuroDerm, Ltd. today announced that results from a phase I study in volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, were presented at the 2013 International Congress of Parkinson's Disease and Movement Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula under development for continuous administration through a sub-cutaneous (SC) delivery patch that...

2013-06-13 08:28:04

NESS ZIONA, Israel, June 13, 2013 /PRNewswire/ -- NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study in healthy volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, have been selected for presentation at the 17th International Congress of Parkinson's Disease and Movement Disorders, June 16th-20th in Sydney, Australia. ND0612 is a proprietary levodopa/carbidopa liquid drug formula under...

2013-06-10 08:30:20

Study Data to be Presented at 17th International Congress of Parkinson's Disease and Movement Disorders EMERYVILLE, Calif., June 10, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. announced today that the Company's Phase 2/3 EASED((TM)) (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia) clinical trial of ADS-5102 (Nurelin((TM)); amantadine HCl extended release) met the study's primary endpoint. ADS-5102 is an investigational...

2013-03-04 04:21:32

NESS ZIONA, Israel, March 4, 2013 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ], Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously sub-cutaneously through a patch pump. It is designed to provide steady levodopa blood levels for the reduction of motor complications in Parkinson's...

2012-11-07 16:27:42

MENLO PARK, Calif., Nov. 7, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced top line results from a Phase 2 clinical trial of DM-1992, Depomed's investigative novel gastric-retentive, extended-release formulation of carbidopa/levodopa, in patients with advanced Parkinson's disease with motor fluctuations. Phase 2 Study Design and ResultsThe trial was a randomized, active-controlled, open-label, crossover study evaluating DM-1992 dosed twice daily against a generic version...